153 related articles for article (PubMed ID: 18824504)
1. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.
Jackaman C; Lew AM; Zhan Y; Allan JE; Koloska B; Graham PT; Robinson BW; Nelson DJ
Int Immunol; 2008 Nov; 20(11):1467-79. PubMed ID: 18824504
[TBL] [Abstract][Full Text] [Related]
2. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
[TBL] [Abstract][Full Text] [Related]
3. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
4. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
6. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
7. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
9. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
10. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
12. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
13. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
[TBL] [Abstract][Full Text] [Related]
15. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
17. Amount of interleukin 12 available at the tumor site is critical for tumor regression.
Colombo MP; Vagliani M; Spreafico F; Parenza M; Chiodoni C; Melani C; Stoppacciaro A
Cancer Res; 1996 Jun; 56(11):2531-4. PubMed ID: 8653692
[TBL] [Abstract][Full Text] [Related]
18. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.
Wall EM; Milne K; Martin ML; Watson PH; Theiss P; Nelson BH
Cancer Res; 2007 Jul; 67(13):6442-50. PubMed ID: 17616705
[TBL] [Abstract][Full Text] [Related]
20. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
